Status: Recruiting
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.
Participants needed: 23
Trial details
Phase: Phase 1Age: 18-79Biological sex: AllType: InterventionalSponsor: Insmed Gene Therapy LLCUpdated: Sep 23, 2026Locations: 7
Eligibility criteria
Participant with body mass index (BMI) ≥18 kilograms per square meter (kg/m²). [+6]
Previous treatment for ALS with cellular or gene therapies. [+1]